Immunic, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 13, 2026, disclosing a net loss of $42.3 million for the third quarter and an accumulated deficit of $717.6 million.

Key Highlights

  • Net loss of $42.309 million for the three months ended September 30, 2026, compared to a net loss of $25.579 million in the same period of 2025, according to the filing.
  • Total operating expenses of $43.369 million in Q3 2026, comprising $23.948 million in research and development and $19.421 million in general and administrative costs.
  • Cash and cash equivalents of $131.963 million as of September 30, 2026, up from $15.483 million at December 31, 2025.
  • Total stockholders' equity of $104.473 million at September 30, 2026, compared to a stockholders' deficit of $6.673 million at December 31, 2025.
  • February 2026 Private Placement contributed $187.263 million net of issuance costs of $12.747 million, the filing disclosed.
  • 1-for-10 reverse stock split became effective April 27, 2026, following Board approval after a Special Meeting of Stockholders held April 14, 2026; all share and per-share data in the filing has been retroactively adjusted.
  • 15,880,822 shares of common stock were outstanding as of November 6, 2026.

Immunic's Q3 2026 Financial Results: Loss Widens, Cash Position Strengthens

According to the filing, Immunic, Inc. (NASDAQ:IMUX) reported a net loss of $42.309 million for the three months ended September 30, 2026, compared to a net loss of $25.579 million for the same quarter in 2025. For the nine months ended September 30, 2026, the company reported a net loss of $108.996 million, versus $77.872 million in the prior-year period. Net loss per share, basic and diluted, was $(0.99) for Q3 2026 and $(2.83) for the nine-month period, compared to $(1.32) and $(5.45), respectively, in the comparable 2025 periods.

Research and development expenses totaled $23.948 million in Q3 2026, up from $20.012 million in Q3 2025, while general and administrative expenses rose to $19.421 million from $5.981 million in the year-ago quarter. The company reported interest income of $1.093 million in Q3 2026, compared to $0.419 million in Q3 2025. The accumulated deficit reached $717.567 million as of September 30, 2026, the filing stated.

The company's cash position increased materially during the nine-month period. The filing attributes a significant portion of this increase to the February 2026 Private Placement, which raised $187.263 million net of issuance costs. The filing also noted that the Board approved a 1-for-10 reverse stock split effective April 27, 2026, following stockholder authorization at a Special Meeting. During Q3 2026, the company recorded stock-based compensation of $13.908 million, and additional shares were issued through warrant and stock option exercises, bringing total shares outstanding to 15,880,822 by November 6, 2026.

What Was Disclosed

Immunic filed its quarterly report covering the period ended September 30, 2026, disclosing a third-quarter net loss of $42.309 million, rising total operating expenses, a materially higher cash balance following a February 2026 private placement, and a 1-for-10 reverse stock split effective April 27, 2026.